Helicobacter pylor
Conditions
Interventions
Control group:PPI-based dual therapy(14-day)
Experimental group :vonoprazan-based dual therapy(10-day)
Experimental group :Vonoprazan-based Bismuth triple therapy(7-day)
Sponsors
First Affiliated Hospital of Zhejiang Chinese Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Participants aged 18-70,no gender limitation; 2. Gastroscopy ruled out digestive tract occupation within 1 year; 3. Confirmed H. pylori infection by at least one of the following tests within 3 months: urea breath test, histology exam and positive bacterial culture; 4. Informed consent signed.
Exclusion criteria
Exclusion criteria: 1. Used antibiotics,bismuth,or acid inhibitor use, including H2 receptor antagonist, PPI or P-CAB within four weeks before inclusion; 2. Current pregnancy or breastfeeding; 3. Allergy to any of the study drugs; 4. History of gastrectomy; 5. Had severe comorbidities or physical or mental diseases; 6. Hepatic or renal dysfunction; 7.Participated in other drug studies within 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Eradication rates of Helicobacter pylori; | — |
Secondary
| Measure | Time frame |
|---|---|
| adverse events;microbiota; | — |
Countries
China
Contacts
Public ContactBin Lu
First Affiliated Hospital of Zhejiang Chinese Medical University
Outcome results
None listed